5697-56-3
5697-56-3
Chemical Structure
Carbenoxolone
- CAS. Nr.: 5697-56-3
- Formula:C34H50O7
- Molecular Weight:570.76
IUPAC Name: (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-((3-carboxypropanoyl)oxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
InChIKey: OBZHEBDUNPOCJG-WBXJDKIVSA-N
SMILES: CC(C)([C@]1([H])CC[C@@]([C@@]2(CC[C@]3(CC[C@](C(O)=O)(C[C@]3(C2=C4)[H])C)C)C)5C)[C@@H](OC(CCC(O)=O)=O)CC[C@]1(C)[C@@]5([H])C4=O
Biological Activity: Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Carbenoxolone | 99.9% | Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbenoxolone-d4 | 99.28% | Carbenoxolone-d4 is the d4 labeled Carbenoxolone (HY-B1588). Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HMGB1-IN-3 | HMGB1-IN-3 (compound E) is a glycyrrhizic acid derivative with strong inhibitory activity against HMGB1 (high mobility group protein 1) and can be used in the study of intracerebral hemorrhage. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbenoxolone disodium | 99.94% | Carbenoxolone disodium is the active metabolite of Glycyrrhizic acid (HY-N0184) and the inhibitor of human 11β-HSD and bacterial 3α, 20β-HSD. Carbenoxolone disodium is an uncoupling agent for gap junctions and a potent inhibitor of Vaccinia virus replication. Carbenoxolone disodium is used for the study of peptic, esophageal and oral ulceration and inflammation. Carbenoxolone disodium inhibits Vaccinia virus replication. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
18β-Glycyrrhetinic acid | 99.88% | 18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhiza uralensis and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
18α-Glycyrrhetinic acid | 99.87% | 18α-Glycyrrhetinic acid, a diet-derived compound, is an inhibitor of NF-kB and an activator of proteasome, which serves as pro-longevity and anti-aggregation factor in a multicellular organism. 18α-Glycyrrhetinic acid induces apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-epi-18β-Glycyrrhetinic acid | 3-epi-18β-Glycyrrhetinic acid is an inhibitor of 11β-HSD1 and 11β-HSD2, with an IC50 of 0.17 μM against 11β-HSD2. 3-epi-18β-Glycyrrhetinic acid acts as a weak substrate for sulfotransferase 2A1. It serves as a biomarker for the toxicity of licorice-related pseudoaldosteronism. 3-epi-18β-Glycyrrhetinic acid is applicable to studies related to pseudoaldosteronism. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3β-Acetoxyurs-12-en-11-one | 99.34% | 3β-Acetoxyurs-12-en-11-one is a ursane triterpenoid with antimicrobial activity, can be isolated from the stem bark of Morus mesozygia and the leaves of Ficus hirta Vahl (Moraceae). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Acetyl-11-keto-ursolic acid | 3-Acetyl-11-keto-ursolic acid (Compound 18) is a triterpenoid compound derived from Eriobotrya japonicaleaves. 3-Acetyl-11-keto-ursolic acid has 11B-hydroxysteroid dehydrogenase 1 (11b-HSD1) inhibitory activity. 3-Acetyl-11-keto-ursolic acid can be used for anti-diabetes research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
β-Amyrenonol acetate | β-Amyrenonol acetate ((3β)-3-(Acetyloxy)olean-12-en-11-one) is a Triterpenoids product that can be isolated from the barks of Clausena excavata. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deloxolone | Deloxolone has the potential for inflammatory, ischemic and proliferative diseases treatment. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Methyl glycyrrhetinate | Methyl glycyrrhetinate, a 18β-glycyrrhetinic acid analogue, is a dual inhibitor of 11β-HSD1 and 11β-HSD2. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Michalski K, et al. Carbenoxolone inhibits Pannexin1 channels through interactions in the first extracellular loop. J Gen Physiol. 2016;147(2):165-174. [Content Brief]
- [2]. Sharma S, et al. Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action. Neurochem Int. 2017;108:481-493. [Content Brief]
- [3]. Crespo Yanguas S, et al. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018;19(3):817. Published 2018 Mar 12. [Content Brief]
- [4]. Hirata K, et al. Formulation of carbenoxolone for delivery to the skin. Int J Pharm. 2013;448(2):360-365. [Content Brief]
